Lantheus Holdings Inc (LNTH) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Lantheus Holdings Inc   (NASDAQ: LNTH)


Lantheus Holdings Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Lantheus Holdings Inc 's ROA in the second quarter of 2026?
Lantheus Holdings Inc achieved a return on average assets (ROA) of 12.04 % in its second quarter of 2026, this is above LNTH's average return on assets of 10.22%.
Lantheus Holdings Inc s assets during the 12 months ending in the second quarter of 2026 are valued at $2 billion

ROA decreased relative to the period ending Mar 31 2026, due to the decline in net income.

However, within the Healthcare sector 81 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 473, from total ROA ranking in the first quarter of 2026 at 639.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Total Assets Change 12.87 % 9.7 % 22.95 % 19.4 % 18.31 %
Y / Y Net Income Change -4.73 % 62.34 % - -78.82 % 26.87 %
Net Income (TTM) in million 275 279 234 168 271
Return On Assets (TTM) 12.04 % 12.58 % 10.77 % 8.12 % 13.74 %
LNTH's Total Ranking # 473 # 639 # 775 # 420 # 445
Total Assets (TTM) in million 2,388 2,254 2,227 2,276 2,116
Seq. Total Assets Change 5.94 % 1.22 % -2.15 % 7.58 % 2.96 %
Seq. Net Income Change -36.64 % 118.93 % 94.76 % -64.74 % 7.96 %

LNTH's 5 Years Annual ROA >> Back to LNTH Management Effectiveness >> Compare LNTH ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 2
Sector # 82
Overall # 495

Return On Assets Statistics
High Average Low
41.74 %
10.22 %
-8.35 %
(Dec 31 2017)   (Dec 31 2021)



  News about Lantheus Holdings Inc Return on Assets ROA

Lantheus Celebrates CMS Payment Enhancements for Radiopharmaceuticals as PYLARIFY Set to Dominate 2025 Market,

Lantheus Applauds CMS 2025 Payment Rule Enhancements for Diagnostic Radiopharmaceuticals: PYLARIFY Positioned for Continued SuccessLantheus Holdings, Inc. a key player in the radiopharmaceutical industry, has recently expressed its commendation for the Centers for Medicare and Medicaid Services (CMS) decision to enhance payment structures related to specialized diagnostic radiopharmaceuticals for the calendar year 2025. This adjustment, highlighted in the final rule for the Medicare Hospital Outpatient Prospective Payment System (OPPS), marks a significant step toward improving patient access to essential diagnostic services. Enhanced Payment Rates and Improved AccessCMS s updated payment rates, posted in Addendum B, demonstrate a recognition of the unique value and necessity of specialized diagnostic radiopharmaceuticals. These agents are pivotal in accurately diagnosing and managing diseases, contributing to significant improvements in patient outcomes. Lantheus argues that by refining the payment structure, healthcare facilities can bolster their financial viability while ensuring that patients have greater access to cutting-edge diagnostic technologies.



Financial Statements
Lantheus Holdings Inc 's Assets $ 2,388 million LNTH's Balance sheet
Lantheus Holdings Inc 's Income $ 75 million Quarterly LNTH's Income Statement
LNTH's Income by Division See LNTH's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 22.95 % 20.53 % 24 % 51.04 % 0.33 %
Total Assets in million 2,227 1,812 1,503 1,212 802
Y / Y Net Income Change -25.25 % -4.35 % 1063.86 % - -
Net Income in million 234 312 327 28 -71
Annual Return On Assets 10.49 % 17.25 % 21.73 % 2.32 % -8.88 %

LNTH's 5 Years Annual ROA >> Back to LNTH Management Effectiveness >> Compare LNTH ROA to its Competitors



Comment on LNTH's ROA in the fiscal year ending 2025
In the fiscal year 2025 Lantheus Holdings Inc 's ROA decreased compared to previous year to 10.49 %, due to deterioration of net income -25.25 % to $233.56 million, from $312.44 million a year ago, as LNTH's assets were $2,227.40 million.


More Return On Assets Ratios
LNTH's' Return on Assets at Yahoo Finance
In Vitro & In Vivo Diagnostic Substances Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
LNTH's Roa Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for LNTH's Competitors
Subscribers only: Roa for Lantheus Holdings Inc 's Suppliers
Subscribers only: Return On Assets for LNTH's Customers

You may also want to know
LNTH's Roi LNTH's Inventory Turnover Ratio LNTH's Growth Rates LNTH's Dividend Comparisons
LNTH's Profitability Ratios LNTH's Asset Turnover Ratio LNTH's Dividend Growth
LNTH's Roe LNTH's Valuation Ratios LNTH's Financial Strength Ratios LNTH's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA
Meiragtx Holdings Plc  29.37 %
Indivior Pharmaceuticals Inc   28.21 %
Qhslab Inc   27.12 %
Adma Biologics Inc   26.58 %
Mettler toledo International Inc   24.86 %
Medpace Holdings Inc   24.84 %
Caredx Inc   24.81 %
Acadia Pharmaceuticals Inc   24.38 %
Eli Lilly And Company  21.97 %
Innoviva Inc   21.64 %
Vaxart Inc   20.85 %
Zevra Therapeutics Inc   20.39 %
Iradimed Corporation  20.36 %
Protalix Biotherapeutics inc   20.09 %
Pro dex Inc   19.87 %
Electromed Inc   19.39 %
United Therapeutics Corporation  17.98 %
Resmed Inc   17.80 %
Krystal Biotech Inc   17.65 %
Chemed Corporation  17.52 %
Zoetis Inc   17.19 %
Vertex Pharmaceuticals Inc  16.88 %
Halozyme Therapeutics Inc   16.55 %
Alnylam Pharmaceuticals Inc   15.76 %
Intuitive Surgical Inc   15.63 %
Healthcare Services Group Inc   15.21 %
Inspire Medical Systems inc   15.21 %
Dexcom Inc   14.87 %
Neurocrine Biosciences Inc   14.73 %
Entera Bio Ltd   14.60 %

Date modified: 2026-09-26T07:21:52+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.